+357 96 030922
info@marketpublishers.com

Solid Dosage Form Market Forecasts to 2034 – Global Analysis By Dosage Form (Tablets, Capsules, Powders & Granules, Lozenges & Pastilles, Pellets & Mini-Tablets, Orally Disintegrating Films, and Other Dosage Forms), Drug Release, Route of Administration, Therapeutic Area, Manufacturing Process, Drug Type, Patient Demographics, End User, Distribution Channel, and By Geography

https://marketpublishers.com/r/SB76207CAABAEN.html
Date: April 2026
Pages: 200
Price: US$ 4,150.00 (Single User License)
ID: SB76207CAABAEN

Abstracts

According to Stratistics MRC, the Global Solid Dosage Form Market is accounted for $1113.6 billion in 2026 and is expected to reach $1856.9 billion by 2034 growing at a CAGR of 6.6% during the forecast period. Solid dosage forms encompass pharmaceutical products such as tablets, capsules, powders, and granules that are administered orally or via other solid-based delivery routes. These formulations represent the most widely adopted drug delivery method due to their stability, precise dosing, patient convenience, and cost-effectiveness in manufacturing. The market is driven by the rising prevalence of chronic diseases, growing geriatric population requiring long-term medication, and continuous innovation in modified-release technologies and patient-centric formulations.

Market Dynamics:

Driver:

Increasing prevalence of chronic diseases

The global rise in chronic conditions such as cardiovascular disorders, diabetes, respiratory ailments, and cancer is fueling sustained demand for solid dosage forms that enable long-term disease management. Patients requiring daily or frequent medication regimens benefit from the convenience and precise dosing that tablets and capsules offer. Pharmaceutical companies are focusing on developing combination products that simplify complex treatment protocols into single solid dosage units, improving patient adherence. As the global burden of chronic diseases continues to escalate, the need for reliable, scalable, and patient-friendly solid formulations remains a cornerstone of pharmaceutical manufacturing and healthcare delivery worldwide.

Restraint:

Complexity in developing poorly soluble drugs

A significant proportion of new chemical entities emerging from drug discovery pipelines exhibit poor aqueous solubility, posing substantial challenges for solid dosage form development. Formulators must employ advanced technologies such as lipid-based systems, nanomilling, and amorphous solid dispersions to achieve adequate bioavailability, increasing development timelines and manufacturing costs. These technical hurdles can delay product launches and limit the feasibility of solid formulations for certain therapeutic classes. Smaller pharmaceutical companies may lack the specialized equipment and expertise required, potentially restricting their ability to compete in markets dominated by complex drug candidates.

Opportunity:

Expansion of continuous manufacturing technologies

The adoption of continuous manufacturing in solid dosage form production offers transformative opportunities for efficiency, quality, and regulatory compliance. Unlike traditional batch processing, continuous manufacturing integrates real-time monitoring and process analytical technology, enabling faster production cycles, reduced waste, and consistent product quality. Regulatory agencies are encouraging these approaches through streamlined approval pathways. As pharmaceutical companies seek to modernize aging facilities and respond to supply chain vulnerabilities exposed during the pandemic, investment in continuous manufacturing platforms for tablets and capsules is accelerating, creating significant growth opportunities for technology providers and contract manufacturing organizations.

Threat:

Intensifying competition from alternative dosage forms

The growing popularity of alternative drug delivery systems such as orally disintegrating tablets, transdermal patches, injectable biologics, and liquid formulations poses a competitive threat to traditional solid dosage forms. Patients seeking greater convenience, faster onset of action, or solutions for swallowing difficulties may prefer these alternatives. Pediatric and geriatric populations, in particular, drive demand for non-solid options. Additionally, the biologic drug revolution favors parenteral delivery, diverting research and development investment away from conventional solid platforms. This shift could erode market share if solid dosage innovation fails to keep pace with evolving patient preferences and therapeutic requirements.

Covid-19 Impact:

The COVID-19 pandemic created both disruptions and opportunities for the solid dosage form market. Initial lockdowns caused supply chain interruptions and reduced outpatient visits, temporarily affecting prescription volumes for chronic medications. However, the rapid development and distribution of oral antivirals for COVID-19 treatment demonstrated the critical role of solid dosage forms in pandemic response. The crisis also accelerated digital health adoption, boosting e?prescriptions and home delivery of medications. Pharmaceutical companies reinforced supply chain resilience by diversifying manufacturing sites and investing in advanced production technologies, positioning the market for sustained growth in the post-pandemic healthcare landscape.

The Pharmaceutical Companies segment is expected to be the largest during the forecast period

The Pharmaceutical Companies segment is expected to account for the largest market share during the forecast period, driven by the central role these organizations play in drug development, manufacturing, and commercialization. Pharmaceutical companies invest heavily in research and development to create innovative solid dosage formulations, including fixed-dose combinations and specialty tablets for complex diseases. Their established quality systems, regulatory expertise, and extensive distribution networks enable them to maintain leadership across therapeutic categories. Additionally, the ongoing trend toward in-house manufacturing of high-value solid dosage products ensures that pharmaceutical companies continue to dominate end-user consumption of solid dosage form technologies and services.

The Online Pharmacies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Online Pharmacies segment is predicted to witness the highest growth rate, reflecting the rapid digital transformation of healthcare delivery and consumer preference for convenient medication access. Patients increasingly turn to licensed e?pharmacies for home delivery of chronic medications, benefiting from competitive pricing, automatic refills, and discreet service. The pandemic permanently shifted buying habits, with many consumers continuing to prefer online channels even after physical pharmacies reopened. Enhanced regulatory frameworks for telemedicine and e?prescribing in major markets further support this channel's expansion. As digital health ecosystems mature, online pharmacies are becoming a preferred distribution route for solid dosage products.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, underpinned by a well-established pharmaceutical industry, strong healthcare infrastructure, and high patient awareness. The presence of numerous multinational pharmaceutical companies, contract manufacturing organizations, and advanced research institutions drives continuous innovation in solid dosage technologies. Favorable reimbursement policies and widespread adoption of digital health tools support robust prescription drug consumption across the region. Additionally, the aging population and high prevalence of chronic diseases such as cardiovascular conditions and diabetes create sustained demand for solid dosage forms, cementing North America's market leadership throughout the forecast period.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, fueled by rapid healthcare infrastructure development, expanding pharmaceutical manufacturing capabilities, and growing chronic disease burden. Countries including China, India, and South Korea are emerging as global hubs for solid dosage production, attracting significant investment in modern manufacturing technologies. Government initiatives promoting generic medicines and universal healthcare coverage increase accessibility to essential solid dosage formulations. Rising disposable incomes and growing patient populations seeking convenient oral therapies further drive market expansion. As multinational pharmaceutical companies

+357 96 030922
info@marketpublishers.com

expand their footprint in the region, Asia Pacific solidifies its position as the fastest-growing market.

Key players in the market

Some of the key players in Solid Dosage Form Market include Catalent Inc., Lonza Group AG, Recipharm AB, Aenova Group, Thermo Fisher Scientific Inc., Pfizer Inc., Novartis AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Limited, Viatris Inc., Sanofi S.A., Abbott Laboratories, Bayer AG, and GlaxoSmithKline plc.

Key Developments:

In March 2026, Catalent announced a global partnership with GelMEDIX for the development and clinical manufacturing of iPSC-derived therapies, utilizing its advanced formulation expertise.

In March 2026, Thermo Fisher Scientific Inc. completed the acquisition of Clario Holdings, Inc., enhancing its clinical trial services and logistics for solid dosage medications globally.

In November 2025, Partnered with AstraZeneca Pharma India to distribute therapies for Hyperkalaemia, focusing on expanding the reach of critical solid dose treatments in emerging markets.

Dosage Forms Covered:

- Tablets
- Capsules
- Powders & Granules
- Lozenges & Pastilles
- Pellets & Mini-Tablets
- Orally Disintegrating Films

Other Dosage Forms

Drug Releases Covered:

Immediate Release

Modified Release

Sustained Release

Extended Release

Controlled Release

Delayed Release (Enteric-Coated)

Targeted Drug Delivery Systems

Route of Administrations Covered:

Oral

Buccal

Sublingual

Therapeutic Areas Covered:

Cardiovascular Diseases

Oncology

Central Nervous System (CNS) Disorders

Anti-Infectives

+357 96 030922
info@marketpublishers.com

Gastrointestinal Disorders

Respiratory Diseases

Metabolic Disorders

Pain Management

Other Therapeutic Areas

Manufacturing Process Covered:

Direct Compression

Wet Granulation

Dry Granulation

Extrusion-Spheronization

Coating Technologies

Film Coating

Sugar Coating

Enteric Coating

Drug Types Covered:

Branded Drugs

Generic Drugs

Over-the-Counter (OTC) Drugs

+357 96 030922
info@marketpublishers.com

Patient Demographics Covered:

- Adult Population
- Pediatric Population
- Geriatric Population

End Users Covered:

- Pharmaceutical Companies
- Contract Development & Manufacturing Organizations (CDMOs)
- Research Institutes

Distribution Channels Covered:

- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies

Regions Covered:

- North America
  - United States
  - Canada
  - Mexico

+357 96 030922
info@marketpublishers.com

- Europe
  - United Kingdom
  - Germany
  - France
  - Italy
  - Spain
  - Netherlands
  - Belgium
  - Sweden
  - Switzerland
  - Poland
  - Rest of Europe
- Asia Pacific
  - China
  - Japan
  - India
  - South Korea
  - Australia
  - Indonesia
  - Thailand

+357 96 030922
info@marketpublishers.com

Malaysia

Singapore

Vietnam

Rest of Asia Pacific

South America

Brazil

Argentina

Colombia

Chile

Peru

Rest of South America

Rest of the World (RoW)

Middle East

Saudi Arabia

United Arab Emirates

Qatar

Israel

Rest of Middle East

Africa

South Africa

Egypt

Morocco

Rest of Africa

What our report offers:

Market share assessments for the regional and country-level segments

Strategic recommendations for the new entrants

Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)

Strategic recommendations in key business segments based on the market estimations

Competitive landscaping mapping the key common trends

Company profiling with detailed strategies, financials, and recent developments

Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling

Comprehensive profiling of additional market players (up to 3)

SWOT Analysis of key players (up to 3)

Regional Segmentation

Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)

Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

13 GLOBAL SOLID DOSAGE FORM MARKET, BY DISTRIBUTION CHANNEL

13.1 Hospital Pharmacies
13.2 Retail Pharmacies
13.3 Drug Stores
13.4 Online Pharmacies

14 GLOBAL SOLID DOSAGE FORM MARKET, BY GEOGRAPHY

14.1 North America
  14.1.1 United States
  14.1.2 Canada
  14.1.3 Mexico
14.2 Europe
  14.2.1 United Kingdom
  14.2.2 Germany
  14.2.3 France
  14.2.4 Italy
  14.2.5 Spain
  14.2.6 Netherlands
  14.2.7 Belgium
  14.2.8 Sweden
  14.2.9 Switzerland
  14.2.10 Poland
  14.2.11 Rest of Europe
14.3 Asia Pacific
  14.3.1 China
  14.3.2 Japan
  14.3.3 India
  14.3.4 South Korea
  14.3.5 Australia
  14.3.6 Indonesia
  14.3.7 Thailand
  14.3.8 Malaysia
  14.3.9 Singapore
  14.3.10 Vietnam
  14.3.11 Rest of Asia Pacific
14.4 South America

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Solid Dosage Form Market Forecasts to 2034 – Global Analysis By Dosage Form (Tablets, Capsules, Powders & Granules, Lozenges & Pastilles, Pellets & Mini-Tablets, Orally Disintegrating Films, and Other Dosage Forms), Drug Release, Route of Administration, Therapeutic Area, Manufacturing Process, Drug Type, Patient Demographics, End User, Distribution Channel, and By Geography

Product link: https://marketpublishers.com/r/SB76207CAABAEN.html

Price: US$ 4,150.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/SB76207CAABAEN.html